Spexis Ltd. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of respiratory therapeutics. The firm focuses on rare, chronic respiratory diseases (CRD) and chronic lung infections in cystic fibrosis. Its product pipeline includes ColiFin, Inhaled Murepavadin, Balixafortide (POL6326), OMPTA, EBX-002, and POL6014 (Lonodelestat). The company was founded by Daniel Obrecht and Jean-Pierre Obrecht in 1996 and is headquartered in Allschwil, Switzerland.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Carlton & United Beverages Pty Ltd., part of Anheuser-Busch InBev SA/NV, is a company headquartered in Southbank, Australia. The firm manufactures and markets alcoholic and non-alcoholic beverages.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA.

Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.

Inprother ApS is a company headquartered in Copenhagen, Denmark, that operates as an immunotherapy company. It was founded in 2011 by Peter Johannes Holst. Jordi Naval is the CEO, in this role since 2021.\nThe company says this about itself: InProTher is a biotechnology company based in Copenhagen, Denmark. The vision of InProTher is to lead the development of novel immunotherapies that target the Human Endogenous Retroviruses (HERVs) as tumor-specific antigens. InProTher will solve bottlenecks and unleash the full potential of immuno-oncology, not only in terms of cancer vaccines but also in further expanding the use of checkpoint inhibitors to multiple indications and patient populations. To date, InProTher has put in place a world-class scientific team and created an emerging product development pipeline, including a leading programme targeted to enter clinics in 2024. Initial investors in InProTher include the BioInnovation Institute (Novo Foundation), and Vaekstfonden (Denmark).

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer treatments better. The lead platform technology, IRX-2, is thought to broadly restore the immune system by overcoming cancer-induced immune suppression. The Company believes that its products can play an important role in helping a wide range of cancer treatments improve and extend the lives of patients. It was founded in 1994 and is headquartered in New York.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Engages in research of medical therapies for diseases

Procept is engaged in the research and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. Procept is developing therapeutics for the treatment of autoimmune disease, organ transplant rejection and infectious diseases, such as AIDS and tuberculosis. The company is located in San Diego. CA

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

CanImGuide is developing a therapeutic platform based around an extraordinary biologic concept and an entirely new mechanism of action for immunomodulation. They have discovered and thoroughly demonstrated, that a previously unknown immunosuppressive peptide named P3028 is formed in malignant tumors through the breakdown of albumin. This intra-tumoral albumin peptide binds to the fundamental receptor.

eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select messenger RNA into proteins that are frequent culprits in key disease driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK 1/2 inhibitor. KICKSTART, a randomized, double-blind, placebo controlled Phase 2b trial of tomivorsertib in NSCLC in combination with pembrolizumab is currently open for enrollment. Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently in the dose-escalation portion of a Phase 1/2 trial, with Phase 2a expansion cohorts expected to initiate in the second half of 2021. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

Navrogen, Inc. is a biotechnology company, which engages in the discovery and development of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. The company was founded by Luigi Grasso and Nicholas C. Nicolaides in 2017 and is headquartered in Philadelphia, PA.

Chameleon is changing the way they treat genetic diseases using gene therapy to deliver corrective genes using multiple systemic dose administrations. Research indicates that 20-30% of all infant fatalities are due to genetic disorders, and for those who survive, treatment options are often limited. Recent breakthroughs in gene therapy are saving lives, but there's still a long way to go. At Chameleon, their goal is to ensure every child can be treated with lower doses and accurate target specificity over time as their condition requires. They are committed to every child and family who suffers from a genetic disorder. Their mission is to make sure every Belle, Abby and Marian live to their 10th birthdays, learn to drive, go to prom and someday have healthy children of their very own.

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network.

The Research Institute at Nationwide Children's Hospital is one of America's ten largest free-standing pediatric research centers and works to enhance the health of children by engaging in research.